Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen

PURPOSE: Anti-endocrine therapy remains the most effective treatment for ER+ breast cancer, but development of resistance is a major clinical complication. Effective targeting of mechanisms that control the loss of ER dependency in breast cancer remains elusive. We analyzed breast cancer-associated...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Brechbuhl, Heather M., Finlay-Schultz, Jessica, Yamamoto, Tomomi M., Gillen, Austin E., Cittelly, Diana M., Tan, Aik C., Sams, Sharon, Pillai, Manoj M., Elias, Anthony D., Robinson, William A., Sartorius, Carol A., Kabos, Peter
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5378660/
https://ncbi.nlm.nih.gov/pubmed/27702820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2851
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items